Differences in cancer care spending and utilization between Medicare beneficiaries receiving chemotherapy in hospital outpatient departments versus physician offices vary by service type.
Jeah Jung, PhD
Advertisement
Articles by Jeah Jung, PhD
Our study provides the first evidence on site-specific Medicare spending on chemotherapy adjusting for patient comorbid illnesses, cancer type, and other cancer-related risks.
Spending on chemotherapy drugs was lower among Medicare beneficiaries who received chemotherapy in hospital outpatient departments than among comparable beneficiaries receiving chemotherapy in physician offices.
This study examined the early impacts of closing the donut hole in Medicare Part D.
Advertisement
Latest Updated Articles
- In-Gap Discounts in Medicare Part D and Specialty Drug Use
September 18th 2017
- The Authors Respond and Stand Behind Their Findings
October 4th 2018
Advertisement
Advertisement
Trending on AJMC
1
EHA 2026 Late Breakers Deliver Practice-Shifting Phase 3 Data and Novel CAR T Approaches Across Hematology
2
Paul Richardson, MD, Calls Mezigdomide “CAR T in a Pill” for Patients With R/R Multiple Myeloma
3
MRD-Guided CLL Treatment Duration: Personalization or Malpractice?
4
Type 5 Diabetes: A Long-Ignored Condition Gets Its Moment
5